Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J Borad, Johannes Voortman, Robert R Mc Williams, Jennifer R. Diamond, Elisabeth G E De Vries, Henk M. Verheul, Christopher H. Lieu, George P. Kim, Yulei Wang, Suzie J. Scales, Divya Samineni, Flavia Brunstein, Younjeong Choi, Daniel J. Maslyar, Gerardo Colon-Otero

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2-2.8 mg/kg; q3w) or weekly (0.8-1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventyone patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n=54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n=17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer.

Original languageEnglish (US)
Pages (from-to)439-447
Number of pages9
JournalMolecular Cancer Therapeutics
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Drug Delivery Systems
Platinum
Ovarian Neoplasms
Appointments and Schedules
Pancreatic Neoplasms
Antibodies
Hypophosphatemia
Antimitotic Agents
Safety
Retreatment
Hyperglycemia
Pharmacokinetics
mesothelin
Therapeutics
Serum
Pharmaceutical Preparations
Neoplasms
monomethyl auristatin E

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. / Weekes, Colin D.; Lamberts, Laetitia E.; Borad, Mitesh J; Voortman, Johannes; Mc Williams, Robert R; Diamond, Jennifer R.; De Vries, Elisabeth G E; Verheul, Henk M.; Lieu, Christopher H.; Kim, George P.; Wang, Yulei; Scales, Suzie J.; Samineni, Divya; Brunstein, Flavia; Choi, Younjeong; Maslyar, Daniel J.; Colon-Otero, Gerardo.

In: Molecular Cancer Therapeutics, Vol. 15, No. 3, 01.03.2016, p. 439-447.

Research output: Contribution to journalArticle

Weekes, CD, Lamberts, LE, Borad, MJ, Voortman, J, Mc Williams, RR, Diamond, JR, De Vries, EGE, Verheul, HM, Lieu, CH, Kim, GP, Wang, Y, Scales, SJ, Samineni, D, Brunstein, F, Choi, Y, Maslyar, DJ & Colon-Otero, G 2016, 'Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer', Molecular Cancer Therapeutics, vol. 15, no. 3, pp. 439-447. https://doi.org/10.1158/1535-7163.MCT-15-0693
Weekes, Colin D. ; Lamberts, Laetitia E. ; Borad, Mitesh J ; Voortman, Johannes ; Mc Williams, Robert R ; Diamond, Jennifer R. ; De Vries, Elisabeth G E ; Verheul, Henk M. ; Lieu, Christopher H. ; Kim, George P. ; Wang, Yulei ; Scales, Suzie J. ; Samineni, Divya ; Brunstein, Flavia ; Choi, Younjeong ; Maslyar, Daniel J. ; Colon-Otero, Gerardo. / Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. In: Molecular Cancer Therapeutics. 2016 ; Vol. 15, No. 3. pp. 439-447.
@article{f385fa5e49fa42d3a24641f771e3d27f,
title = "Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer",
abstract = "DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2-2.8 mg/kg; q3w) or weekly (0.8-1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventyone patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n=54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n=17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer.",
author = "Weekes, {Colin D.} and Lamberts, {Laetitia E.} and Borad, {Mitesh J} and Johannes Voortman and {Mc Williams}, {Robert R} and Diamond, {Jennifer R.} and {De Vries}, {Elisabeth G E} and Verheul, {Henk M.} and Lieu, {Christopher H.} and Kim, {George P.} and Yulei Wang and Scales, {Suzie J.} and Divya Samineni and Flavia Brunstein and Younjeong Choi and Maslyar, {Daniel J.} and Gerardo Colon-Otero",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-15-0693",
language = "English (US)",
volume = "15",
pages = "439--447",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer

AU - Weekes, Colin D.

AU - Lamberts, Laetitia E.

AU - Borad, Mitesh J

AU - Voortman, Johannes

AU - Mc Williams, Robert R

AU - Diamond, Jennifer R.

AU - De Vries, Elisabeth G E

AU - Verheul, Henk M.

AU - Lieu, Christopher H.

AU - Kim, George P.

AU - Wang, Yulei

AU - Scales, Suzie J.

AU - Samineni, Divya

AU - Brunstein, Flavia

AU - Choi, Younjeong

AU - Maslyar, Daniel J.

AU - Colon-Otero, Gerardo

PY - 2016/3/1

Y1 - 2016/3/1

N2 - DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2-2.8 mg/kg; q3w) or weekly (0.8-1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventyone patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n=54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n=17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer.

AB - DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2-2.8 mg/kg; q3w) or weekly (0.8-1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventyone patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n=54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n=17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84964389814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964389814&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-15-0693

DO - 10.1158/1535-7163.MCT-15-0693

M3 - Article

C2 - 26823490

AN - SCOPUS:84964389814

VL - 15

SP - 439

EP - 447

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -